Spero Therapeutics Free Cash Flow (FCF) History (SPRO)
Spero Therapeutics reported −$86.0M in free cash flow for fiscal 2020, a decrease of $35.7M from the previous fiscal year, with a free cash flow margin of −33344.57%.
View full Spero Therapeutics company overviewSpero Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2020 | 2020-12-31 | −$86.0M | −$35.7M | — | −33344.57% |
| 2019 | 2019-12-31 | −$50.3M | −$8.3M | — | −1061.45% |
| 2018 | 2018-12-31 | −$42.1M | −$2.9M | — | −1060.54% |
| 2017 | 2017-12-31 | −$39.1M | −$9.3M | — | −1977.67% |
| 2016 | 2016-12-31 | −$29.8M | −$19.9M | — | −8892.24% |
| 2015 | 2015-12-31 | −$9.8M | — | — | — |
Spero Therapeutics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2021 | 2021-09-30 | −$5.0M | $18.5M | — | −699.44% |
| Q4 2020 | 2020-12-31 | −$16.4M | $1.1M | — | — |
| Q3 2020 | 2020-09-30 | −$21.3M | −$11.6M | — | −56092.11% |
| Q2 2020 | 2020-06-30 | −$24.9M | −$12.8M | — | −48845.10% |
| Q1 2020 | 2020-03-31 | −$23.4M | −$12.4M | — | −13850.89% |
| Q4 2019 | 2019-12-31 | −$17.5M | — | — | −2513.79% |
| Q3 2019 | 2019-09-30 | −$9.7M | — | — | −5625.58% |
| Q2 2019 | 2019-06-30 | −$12.2M | — | — | −18144.78% |
| Q1 2019 | 2019-03-31 | −$11.0M | — | — | −289.07% |
Spero Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$9.8M to −$86.0M, a net decrease of $76.2M. Spero Therapeutics's latest reported quarter, Q3 2021, generated −$5.0M in free cash flow, an increase of $18.5M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Spero Therapeutics filings at SEC.gov ↗